Abstract
Johan Vekemans, Katherine O'Brien, and Jeremy Farrar discuss recent breakthroughs in the search for a highly effective tuberculosis vaccine.
Highlights
The United Nation’s High-Level Meeting on TB renewed the commitment to fight TB, but it is clear that current approaches are insufficient, highlighting the importance of research and development for new tools [2]
Advancing the evaluation of M72/AS01 is a major priority, it is not the only important progress in the TB vaccine field. Another promising breakthrough emerged from a recent study in South Africa evaluating the effect of Bacillus Calmette-Guerin (BCG) revaccination in people vaccinated with BCG at birth and with no evidence of latent TB infection (LTBI) [7]
The world needs better operating models supporting prompt progress from vaccine efficacy proof-of-concept to evaluation for use and impact in support of policy decision and funding for implementation
Summary
A vaccine preventing pulmonary tuberculosis (TB) in adults is needed but has long been considered an elusive goal. The United Nation’s High-Level Meeting on TB renewed the commitment to fight TB, but it is clear that current approaches are insufficient, highlighting the importance of research and development for new tools [2].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
